Arctic Bioscience – Mandatory notification of trade by CEO Christer L. Valderhaug

Christer L. Valderhaug, CEO of Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK 15.4925 per share. Following the transaction, Christer L. Valderhaug holds 10,000 shares and 250,000 share options in Arctic Bioscience.

Please refer to the attached notification of trading for further details. 

This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

For more information, please contact

Danielle Glenn

CFO Arctic Bioscience

Phone: +47 909 98 201

E-mail: danielle@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing nutraceutical and pharmaceutical products based on unique bioactive marine compounds from herring roe.

The company is developing HRO350 – a novel investigational drug candidate based on herring roe. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.

Herring roe contains lipids that are essential in maintaining cell membranes and omega -3 fatty acids that contribute to the normal functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand. The strategy is to switch sales from bulk to finished goods and focus markets are USA and China.

Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.